Leon Wang's Stock Ratings

Barclays Analyst

Leon Wang is an analyst at Barclays. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 04/02/2025

Overall Average Return

26.8%

Smart Score

68%

Overall Average Return Percentile

86th

Number of Ratings

14
Buy NowGet Alert
05/29/2024INSMBuy Now
Insmed
$72.22-12.77%
Leon Wang68%
$40 → $63MaintainsOverweightGet Alert
05/10/2024RAPTBuy Now
RAPT Therapeutics
$1.17241.88%
Leon Wang68%
$13 → $4DowngradeOverweight → Equal-WeightGet Alert
04/11/2024INSMBuy Now
Insmed
$72.22-44.61%
Leon Wang68%
$37 → $40MaintainsOverweightGet Alert
02/21/2024RAPTBuy Now
RAPT Therapeutics
$1.171011.11%
Leon Wang68%
$35 → $13MaintainsOverweightGet Alert
09/12/2023MLTXBuy Now
MoonLake
$37.0059.45%
Leon Wang68%
$41 → $59MaintainsEqual-WeightGet Alert
06/27/2023MLTXBuy Now
MoonLake
$37.0010.8%
Leon Wang68%
$28 → $41MaintainsEqual-WeightGet Alert
06/15/2023MLTXBuy Now
MoonLake
$37.00-24.33%
Leon Wang68%
→ $28Initiates → Equal-WeightGet Alert
06/15/2023RAPTBuy Now
RAPT Therapeutics
$1.172891.45%
Leon Wang68%
→ $35Initiates → OverweightGet Alert
01/20/2023INSMBuy Now
Insmed
$72.22-51.54%
Leon Wang68%
$37 → $35MaintainsOverweightGet Alert
01/12/2023CINCBuy Now
CinCor Pharma
Leon Wang68%
$22 → $31DowngradeOverweight → Equal-WeightGet Alert
12/08/2022INSMBuy Now
Insmed
$72.22-48.77%
Leon Wang68%
→ $37Initiates → OverweightGet Alert
12/08/2022CINCBuy Now
CinCor Pharma
Leon Wang68%
→ $22Initiates → OverweightGet Alert
12/07/2022INSMBuy Now
Insmed
$72.22-48.77%
Leon Wang68%
→ $37Initiates → OverweightGet Alert
12/07/2022CINCBuy Now
CinCor Pharma
Leon Wang68%
→ $22Initiates → OverweightGet Alert